Cargando…

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants

The rapid widespread Omicron subvariant BA.5 of SARS-CoV-2 has become a potential imminent pandemic threat, but available vaccines lack high efficacy against this subvariant. Thus, it is urgent to find highly protective vaccination strategies within available SARS-CoV-2 vaccines. Here, by using a SA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Jiaying, Liu, Shuo, Cui, Tingting, Li, Jingxin, Zhu, Fengcai, Zhong, Nanshan, Huang, Weijin, Zhao, Zhuxiang, Wang, Zhongfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639505/ https://www.ncbi.nlm.nih.gov/pubmed/36197655 http://dx.doi.org/10.1080/22221751.2022.2132881

Ejemplares similares

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
por: Das, Rituparna, et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
por: Liang, Ziteng, et al.
Publicado: (2023)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
por: Liu, Shuo, et al.
Publicado: (2023)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
por: Tukhvatulin, Amir I., et al.
Publicado: (2022)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort
por: Zhu, Liguo, et al.
Publicado: (2023)

Heterologous COVID-19 vaccination in pregnant women: Comment
por: Sookaromdee, Pathum, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
por: Wang, Meiyu, et al.
Publicado: (2021)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
por: Gao, Xingsu, et al.
Publicado: (2022)

Willingness of college students to receive COVID-19 heterologous vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants
por: Wang, Junxiang, et al.
Publicado: (2022)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

COVID-19 vaccine booster dose hesitancy among key groups: A cross-sectional study
por: Huang, Min, et al.
Publicado: (2023)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
por: Wang, Xuan-Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_njqcpglos6aljkt7j6v8clj2sg